We are live on ! Find out more
DSGN icon

Design Therapeutics

43 hedge funds and large institutions have $755M invested in Design Therapeutics in 2021 Q1 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.87% more ownership

Funds ownership: 0%47.87% (+48%)

Holders
43
Holders Change
+43
Holders Change %
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
43
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

DSGN Hedge Fund Activity: Q1 2021 in Review

43 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2021, worth a combined $755M.

Buyers outnumbered sellers: 43 funds opened new DSGN positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $173M.

  • 43 institutional investors held Design Therapeutics (DSGN) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $755M of Design Therapeutics stock for Q1 2021.
  • 43 funds opened new Design Therapeutics positions in Q1 2021 and 0 closed out, a net change of +43 holders.
  • The largest Design Therapeutics buyer in Q1 2021 was Cormorant Asset Management, an estimated $173M added.

Based on aggregated 13F filings for Q1 2021.